French Indochina was a grouping of territories.
Mavoglurant -LRB- AFQ056 -RRB- is an experimental drug candidate for the treatment of fragile X syndrome .. fragile X syndrome. fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 -LRB- mGLU5 -RRB- .. antagonist. receptor antagonist. metabotropic glutamate receptor 5. metabotropic glutamate receptor 5. Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials .. development. drug development. Novartis. Novartis. Phase IIb / III dose finding and evaluation trials for fragile X-syndrome have been discontinued by the end of 2014 .. Otherwise , it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome .. fragile X syndrome. fragile X syndrome. Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia .. Levodopa-induced dyskinesia. Levodopa-induced dyskinesia. In 2007 , Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking , but no results had been published up till now .. Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder .. Novartis. Novartis. obsessive compulsive disorder. obsessive compulsive disorder. Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results .. fragile X syndrome. fragile X syndrome. development. drug development. Novartis. Novartis